Supreme Court set to consider six pharmaceutical petitions challenging IRA drug negotiation
The Supreme Court is considering whether to take up six pharmaceutical companies' petitions challenging the IRA's Medicare drug negotiation program after lower courts ruled the program constitutional.
Objective Facts
The Supreme Court is set to consider at its conference Thursday (May 14) whether to take up petitions from six pharmaceutical companies to consider the legality of the Inflation Reduction Act's Medicare drug negotiation program, after industry has suffered numerous losses with lower courts ruling the program is constitutional. All six drug manufacturers that lost their appeals in the Second and Third Circuits—AstraZeneca, Janssen, Bristol-Myers Squibb, Novo Nordisk, Boehringer Ingelheim, and Novartis—have asked the Supreme Court to intervene. Despite pursuing claims on multiple grounds, pharmaceutical companies and industry groups have failed on the merits in 10 district court decisions and six circuit court decisions. Several factors suggest the Supreme Court is unlikely to take up these cases—at least not this term, as there are no circuit splits yet. The program has already been implemented by both the Biden and Trump administrations, with negotiated prices taking effect on January 1, 2026 for the first ten drugs, with all manufacturers participating.
Left-Leaning Perspective
Public Citizen and patient advocacy organizations have framed the Supreme Court's consideration of these petitions as potentially catastrophic for affordable drug access. The Petrie-Flom Center at Harvard Law School, in an analysis published in February 2026, emphasized that the decision could be "literally life or death" for millions of Americans, noting that patients themselves would have seen savings of $1.5 billion from the first set of negotiations and $685 million from the second set. Patient advocates stress these savings represent the difference between patients affording life-changing medications and rationing or going without medication. Progressive voices supporting the program cite extensive evidence of its effectiveness. The Congressional Budget Office estimates the program will save nearly $100 billion in the first six years of negotiated drug prices, with savings reaching $25 billion in 2031 alone, according to Public Citizen's January 2026 analysis. Patient advocacy groups also highlight that every court that has considered substantive challenges to the program has ruled against the pharmaceutical industry. Legal experts from the Health Affairs Forefront, published in March 2026, emphasized that pharmaceutical companies' constitutional claims face significant legal obstacles under existing doctrine. Left-leaning coverage downplays pharma's concerns about innovation losses, with analysts noting that research has found industry fears about stifled innovation may be overblown and that the program does not require manufacturers to relinquish drugs—it merely sets price ceilings. Progressive sources emphasize the stark reality that Americans pay three times as much as people in other countries for the same drugs, and that public support for price negotiation exceeds 80 percent.
Right-Leaning Perspective
Pharmaceutical companies and business groups have presented the IRA drug negotiation program as a constitutional violation disguised as voluntary negotiation. Bristol Myers Squibb and Janssen Pharmaceuticals argued in their December 2025 Supreme Court petition that the program makes manufacturers "an offer [they can't] refuse," citing the threat of enterprise-crippling tax penalties of up to 1900 percent of daily drug sales. The U.S. Chamber of Commerce filed amicus briefs arguing the program's pricing provisions are "illusory" negotiations and risk doing "irremediable damage to investment in research and development in the U.S. pharmaceutical sector." Right-leaning industry arguments focus on constitutional property rights and due process. Merck called the process a "sham" and "extortion," while AstraZeneca's September 2025 petition argued the IRA deprives the company of constitutionally protected interests and "upends the biopharmaceutical ecosystem." The Chamber contends the statute employs "crippling penalties and other tools to coerce manufacturers to sell their property to third parties at below-market prices." Industry also emphasizes that participating in Medicare price negotiations was not contemplated when companies made billion-dollar research investments. Right-leaning coverage emphasizes the lack of true negotiation and innovation concerns. Conservative sources note that manufacturers who participated in the first round of negotiations did so under duress rather than genuine choice. Industry representatives stress that the program's implementation through CMS guidance rather than formal rulemaking compounds the constitutional concerns, particularly after the Supreme Court's Loper Bright decision ending Chevron deference to agencies.
Deep Dive
The May 14, 2026 Supreme Court conference decision on six pharmaceutical petitions represents a critical moment in the contested politics of drug pricing, though institutional factors suggest the Court is likely to decline review. The petitions stem from three years of litigation in which pharmaceutical manufacturers have challenged the IRA's Medicare Drug Price Negotiation Program on constitutional and statutory grounds—First Amendment compelled speech, Fifth Amendment takings and due process violations, Eighth Amendment excessive fines, and Administrative Procedure Act claims. Notably, every court that has reviewed these challenges on the merits has ruled against the manufacturers, creating a uniform judicial precedent. The pharmaceutical industry's strategy reveals genuine desperation: despite unprecedented legal losses (10 district court defeats, 6 appellate defeats) and the program's continued implementation under both the Biden and Trump administrations, manufacturers are pushing the Supreme Court to intervene. The six manufacturers who petitioned (AstraZeneca, Janssen, Bristol-Myers Squibb, Novo Nordisk, Boehringer Ingelheim, and Novartis) argue the program forces them to accept below-market prices under threat of 1900-percent penalty taxes—effectively coercing participation in what they characterize as sham negotiation. Patient advocates counter that the first two rounds of negotiations have achieved 38-84 percent price reductions, generating $1.5 to $2 billion in patient savings without halting drug development, and that all manufacturers ultimately chose to participate anyway, suggesting voluntary participation works in practice. The Trump administration, which took office in 2025, has quietly continued the program's implementation and is even pursuing additional drug pricing controls through MFN pricing initiatives, suggesting bipartisan acceptance that the program is durable policy. The Supreme Court faces institutional obstacles to taking these cases. Health Affairs analysis notes that absent a circuit split—which does not yet exist—the Court has "less reason to intervene and does not seem eager to do so." The Court previously rescheduled the AstraZeneca petition from January 2026 to May, and has liberally granted filing deadline extensions, signaling reluctance to rush into the case. The IRA provides detailed statutory guidance and limitations on CMS discretion, making nondelegation challenges difficult under existing doctrine; lower courts have applied settled law on voluntary program participation rather than departing from precedent in ways that would trigger Supreme Court intervention. Moreover, the program is already fully implemented—negotiated prices took effect January 1, 2026, and manufacturers have all complied—reducing the urgency courts typically feel when reviewing preliminary injunction denials. The question for Supreme Court observers is whether the Court will see this as a genuine constitutional crisis warranting intervention or as settled statutory interpretation where lower courts have applied existing doctrine competently to a new Medicare scheme.